PL

Plumbline Life Sciences, Inc.

Develops DNA vaccines and therapeutics for companion animals and livestock.

222670 | KO

Overview

Corporate Details

ISIN(s):
KR7222670002
LEI:
Country:
South Korea
Address:
서울특별시 서초구 반포대로 222성의교정 성의회관 1315호, 서울특별시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Plumbline Life Sciences, Inc. is an animal biopharmaceutical company that develops a new class of nucleic acid-based DNA medicines. Utilizing its proprietary DNA platform technology, the company creates vaccines and therapeutics for the global animal health market, targeting both companion animals and livestock. Its development pipeline includes 'Renewdog', a first-in-class DNA therapeutic for canines, and other products for applications such as oncology and infectious disease prevention. The company's technology is designed to produce potent, safe, and room-temperature stable treatments with a simplified manufacturing process.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-06-12 00:00
Regulatory News Service
기업설명회(IR)개최결과
Korean 6.6 KB
2025-06-11 00:00
Share Issue/Capital Change
증권발행결과(자율공시)
Korean 5.3 KB
2025-06-02 00:00
Share Issue/Capital Change
주요사항보고서(유상증자결정)
Korean 32.5 KB
2025-05-29 00:00
Report Publication Announcement
기업설명회(IR)개최
Korean 7.0 KB
2025-05-16 00:00
Share Issue/Capital Change
[기재정정]전환청구권행사
Korean 19.7 KB
2025-05-12 00:00
Share Issue/Capital Change
전환청구권행사
Korean 16.5 KB
2025-04-28 00:00
Share Issue/Capital Change
[기재정정]주요사항보고서(전환사채권발행결정)
Korean 40.7 KB
2025-04-07 00:00
Share Issue/Capital Change
[기재정정]주요사항보고서(전환사채권발행결정)
Korean 41.6 KB
2025-04-07 00:00
Share Issue/Capital Change
[기재정정]주요사항보고서(전환사채권발행결정)
Korean 40.2 KB
2025-04-03 00:00
Transaction in Own Shares
자기주식처분결과보고서
Korean 18.3 KB
2025-03-28 00:00
Transaction in Own Shares
주요사항보고서(자기주식처분결정)
Korean 31.1 KB
2025-03-26 00:00
Post-Annual General Meeting Information
정기주주총회결과
Korean 17.9 KB
2025-03-26 00:00
Remuneration Information
주식매수선택권부여에관한신고
Korean 20.6 KB
2025-03-20 00:00
Share Issue/Capital Change
증권발행결과(자율공시) (제3자배정 유상증자)
Korean 5.6 KB
2025-03-19 00:00
Audit Report / Information
사업보고서 (2024.12)
Korean 299.7 KB

Automate Your Workflow. Get a real-time feed of all Plumbline Life Sciences, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Plumbline Life Sciences, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Plumbline Life Sciences, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Aprogen, Inc Logo
Develops and manufactures novel biologics and biosimilars for cancer and arthritis treatments.
South Korea
007460
Develops drugs for fibrosis, inflammation, and cancer using NOX inhibitor & CAF modulation tech.
South Korea
293780
Aptahem AB Logo
Develops RNA aptamers to treat acute, life-threatening conditions like sepsis.
Sweden
APTA
Aptamer Sciences Inc Logo
Develops aptamer-based therapeutics and diagnostics for oncology and solid tumors.
South Korea
291650
Aptevo Therapeutics Inc. Logo
Developing multi-specific antibody immunotherapies for hematologic and solid tumor cancers.
United States of America
APVO
Aptorum Group Ltd Logo
Biopharma developing novel therapeutics for oncology, infectious and metabolic diseases.
United States of America
APM
Aquestive Therapeutics, Inc. Logo
Develops oral film drugs for CNS disorders and severe allergies.
United States of America
AQST
Arbutus Biopharma Corp Logo
A clinical-stage virology company developing a functional cure for chronic hepatitis B (HBV).
United States of America
ABUS
Arcellx, Inc. Logo
Engineering controllable cell therapies for cancer and autoimmune diseases.
United States of America
ACLX
Arctic Bioscience Logo
Develops pharma & nutra ingredients from marine lipids for autoimmune & wellness applications.
Norway
ABS

Talk to a Data Expert

Have a question? We'll get back to you promptly.